Targeting TRP Channels: from Drug Development to Clinical Trials
A special issue of Medical Sciences (ISSN 2076-3271).
Deadline for manuscript submissions: closed (30 April 2019) | Viewed by 18095
Interests: the capsaicin receptor TRPV1; small molecule TRP inhibitors; TRP channels and cancer; neurogenic inflammation and cancer; cancer pain
Special Issues, Collections and Topics in MDPI journals
With over 300 reviews during the past 5 years, Transient Receptor Potential (TRP) channels are among the most discussed therapeutic targets, covering areas from the clinically relevant (such as pain and inflammation) to the more obscure (like sperm quality and antischistosomal activity). Indeed, the vanilloid (capsaicin) receptor TRPV1 alone, the founding member of the TRP family, has been subject to 2300 papers since 2013. So, why add to this growing mountain of literature? The main reason is the extremely rapid change in this field. For example, TRPV1 antagonists were ushered into clinical trials with record speed within ten years of the cloning of TRPV1, where most flamed out due to a combination of unforeseen side-effects, like hyperthermia and compromised heat pain sensation. However, new-generation TRPV1 antagonists that do not perceptibly change body temperature are already making a comeback, not only as potential analgesic drugs, but also for indications like diabetes.
In 2016, Pharmaceuticals, a sister journal of Medical Sciences, published a well-received, but admittedly incomplete collection of reviews on TRP channels as therapeutic targets (“old thoughts, new concepts”), which is now also available as an eBook. We wish to follow this up with a more clinically oriented collection of review and research articles on TRP channels.
We look forward to your contributions.
Dr. Arpad Szallasi
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medical Sciences is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Transient receptor potential channels
- therapeutic target
- new generation TRVP1 antagonists